CLL has evolved over time under the visionary guidance of its founder and managing director Mr. Navneet Gupta who is a first generation entrepreneur. His technical and managerial skills have resulted in consistent growth of the company and ethical working environment amongst employees.
Back in 1995, CLL started its operation with the production of Isoniazid (anti-tuberculosis) and niacinamide (Vitamin). In 2003 CLL started manufacturing niacin for Jubilant Lifesciences in bulk quantity under CRAMS model and has recently emerged as one of the nation’s top niacin manufacturers in terms of capacity. With a strong R&D team and expansion plans, new modules were set up over the years and APIs such as Aceclofenac and Tramadol HCL were developed and put into the manufacturing pipeline followed by Clopidogrel Bisulphate, Etodolac and other major molecules involving complex chemistry. This development led to company’s compelling nation wide presence.
CLL is promoted by-
Mr. Navneet Gupta as the Managing Director.
Mrs Neeru Gupta as the Director.
Mr. Kishore Deshmukh as the Technical Director.
Mission & Vision
Mission and Vision
To provide medicines of exceptional quality with consistent innovation while contributing towards a clean healthcare environment of society.
Striving to become a leader in the Pharmaceutical Industry with a significant global presence by providing quality, innovation and customer satisfaction.
Established in 1995, Cadchem Laboratories Limited (CLL) has progressed into the field of developing and manufacturing niche Active Pharmaceutical Ingredients (API) and intermediates. It has emerged as a key player in Indian pharmaceutical industry with a considerable growth and a front-end presence across market.
CLL has a dedicated state-of-the-art WHO-GMP Approved Manufacturing and R&D facility situated in Punjab, India. Manufacturing capability has reformed CLL into one of India’s largest manufacturer’s of several APIs in the field of Cardiovascular, CNS, Anti-platelets, Anti fungals and Anti-Inflammatory with focus to expand and offer cost competitive APIs in these therapeutic segments.
Quality is the prime focus of CLL, attracting reputed global and Indian companies. For next three years, CLL has aggressive planning to enter semi-regulated and regulated markets starting with Latin America, Asia and Europe. Moral agenda is of high importance amongst the employees and management. By providing operational excellence and stringent quality, company has been aiming to build a healthier society and work towards achieving its healthcare goal.